Sara Merler

10PUBLICATIONS
82CO-AUTHORS
Toxicology (incl. clinical toxicology)Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Aug 27, 2026
Imaging and Clinical Correlates of [177Lu]Lu-PSMA PET-Defined Eligibility in De Novo Metastatic Prostate Cancer.

|May 28, 2026
EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression.

|Dec 11, 2025
Predicting Toxicities and Survival Outcomes in De Novo Metastatic Hormone-Sensitive Prostate Cancer Using Clinical Features, Routine Blood Tests and Their Early Variations.

Giuseppe Salfi, Martino Pedrani, Amos Colombo

|Jan 11, 2025
The Emerging Predictive and Prognostic Role of Aggressive-Variant-Associated Tumor Suppressor Genes Across Prostate Cancer Stages.

Martino Pedrani, Jessica Barizzi, Giuseppe Salfi

|May 16, 2023
Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 Study.

Sara Elena Rebuzzi, Matteo Brunelli, Francesca Galuppini

|Apr 29, 2022
Incidence of grade 3-4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis.

Alessandro Rizzo, Veronica Mollica, Sara Merler

Pageof 2

Frequent Collaborators

5 joint publications

Silke Gillessen

5 joint publications

Ricardo Pereira Mestre

4 joint publications

Martino Pedrani

3 joint publications

Sebastiano Buti